Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M92,048Revenue (TTM) $M17,618Net Margin (%)16.3Altman Z-Score5.7
Enterprise Value $M94,293EPS (TTM) $1.7Operating Margin %16.3Piotroski F-Score4
P/E(ttm)32.4Beneish M-Score-1.9Pre-tax Margin (%)21.8Higher ROA y-yY
Price/Book6.210-y EBITDA Growth Rate %-3.5Quick Ratio1.4Cash flow > EarningsN
Price/Sales5.25-y EBITDA Growth Rate %-18.4Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow672y-y EBITDA Growth Rate %41.7ROA % (ttm)9.0Higher Current Ratio y-yN
Dividend Yield %2.7PEG--ROE % (ttm)19.5Less Shares Outstanding y-yN
Payout Ratio %88.0Shares Outstanding M1,671ROIC % (ttm)12.5Gross Margin Increase y-yN

Gurus Latest Trades with BMY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMYRonald Muhlenkamp 2016-06-30 Reduce-0.8%$63.88 - $74.29
($70.56)
$ 55.09-22%Reduce -14.54%181,340
BMYVanguard Health Care Fund 2016-06-30 Reduce-0.35%$63.88 - $74.29
($70.56)
$ 55.09-22%Reduce -5.23%45,257,309
BMYT Rowe Price Equity Income Fund 2016-06-30 Reduce-0.21%$63.88 - $74.29
($70.56)
$ 55.09-22%Reduce -17.52%3,325,000
BMYMario Gabelli 2016-06-30 Reduce-0.01%$63.88 - $74.29
($70.56)
$ 55.09-22%Reduce -5.26%619,627
BMYKeeley Asset Management Corp 2016-06-30 Buy 0.01%$63.88 - $74.29
($70.56)
$ 55.09-22%New holding2,960
BMYKen Fisher 2016-06-30 Add$63.88 - $74.29
($70.56)
$ 55.09-22%Add 1.89%648,107
BMYRon Baron 2016-06-30 Add$63.88 - $74.29
($70.56)
$ 55.09-22%Add 1.85%114,941
BMYFirst Eagle Investment 2016-06-30 Reduce$63.88 - $74.29
($70.56)
$ 55.09-22%Reduce -10.92%11,529
BMYDodge & Cox 2016-06-30 Reduce$63.88 - $74.29
($70.56)
$ 55.09-22%Reduce -1.77%72,158
BMYVanguard Health Care Fund 2016-03-31 Add0.21%$58.87 - $68.79
($63.1)
$ 55.09-13%Add 3.29%47,754,809
BMYT Rowe Price Equity Income Fund 2016-03-31 Reduce-0.15%$58.87 - $68.79
($63.1)
$ 55.09-13%Reduce -10.82%4,031,100
BMYKen Fisher 2016-03-31 Add0.07%$58.87 - $68.79
($63.1)
$ 55.09-13%Add 371.85%636,060
BMYRon Baron 2016-03-31 Buy 0.04%$58.87 - $68.79
($63.1)
$ 55.09-13%New holding112,848
BMYMario Gabelli 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 55.09-13%Add 2.29%654,005
BMYKahn Brothers 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 55.09-13%Add 1.90%28,583
BMYRonald Muhlenkamp 2016-03-31 Add0.01%$58.87 - $68.79
($63.1)
$ 55.09-13%Add 0.21%212,200
BMYRuane Cunniff 2016-03-31 Sold Out $58.87 - $68.79
($63.1)
$ 55.09-13%Sold Out0
BMYDodge & Cox 2016-03-31 Reduce$58.87 - $68.79
($63.1)
$ 55.09-13%Reduce -5.16%73,458
BMYT Rowe Price Equity Income Fund 2015-12-31 Reduce-0.26%$59.88 - $70.71
($66.18)
$ 55.09-17%Reduce -18.01%4,520,000
BMYVanguard Health Care Fund 2015-12-31 Add0.12%$59.88 - $70.71
($66.25)
$ 55.09-17%Add 1.95%46,232,449
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ANDREOTTI LAMBERTODirector 2016-09-08Sell21,600$56.87-3.13view
ANDREOTTI LAMBERTODirector 2016-08-25Sell23,200$59.17-6.9view
ANDREOTTI LAMBERTODirector 2016-07-08Sell23,200$74.45-26view
ANDREOTTI LAMBERTODirector 2016-06-28Sell23,200$72.14-23.63view
Elicker John ESVP, Public Affairs & IR 2016-06-14Sell11,820$72.69-24.21view
Bancroft Charles AEVP & CFO 2016-05-20Sell30,201$70.79-22.18view
Caldarella Joseph CSVP & Controller 2016-05-16Sell3,519$72.47-23.98view
LEUNG SANDRAEVP, General Counsel 2016-05-06Sell72,544$70.39-21.74view
ANDREOTTI LAMBERTODirector 2016-05-05Sell23,200$70.54-21.9view
Caforio GiovanniCEO 2016-05-03Sell34,594$71.31-22.75view

Press Releases about BMY :

Quarterly/Annual Reports about BMY:

News about BMY:

Articles On GuruFocus.com
52-Week Company Lows Sep 22 2016 
52-Week Company Lows Sep 15 2016 
Is Bristol-Myers Squibb Presenting an Opportunity? Sep 08 2016 
52-Week Company Lows Sep 08 2016 
52-Week Company Lows Sep 02 2016 
Pharmaceuticals are the New Bonds Aug 30 2016 
Merck Offers Value and Steady Dividend Growth Aug 24 2016 
Spiros "Sig" Segalas' Capital Appreciation Fund 2nd Quarter Commentary Aug 18 2016 
Bristol-Myers Squibb Makes a Good Investment Aug 16 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 

More From Other Websites
Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo Sep 28 2016
Bristol-Myers, Abercrombie & Fitch Slide into Wednesday’s 52-Week Low Club Sep 28 2016
Exxon, Chevron Dominate DJIA Wednesday Sep 28 2016
Top trades for the 2nd half: BMY, CRM & more Sep 28 2016
Bristol-Myers Squibb Slides Into Value-Stock Territory Sep 28 2016
Big Pharma partners with another Bay Area company in cancer immunotherapy quest Sep 27 2016
Bristol-Myers to test Opdivo with Nektar drug for several cancers Sep 27 2016
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate... Sep 27 2016
Bristol, Nektar Research Pact Aims to Boost Efficacy of Cancer Immunotherapy Sep 27 2016
Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate... Sep 27 2016
Gilead Sciences Focuses on a Strong Inorganic Growth Strategy Sep 23 2016
AVEO Collaborates With Bristol-Myers Squibb for RCC Drug (AVEO, BMY) Sep 22 2016
Bristol-Myers Squibb Stock Is Down, but That Means You Should Buy Sep 22 2016
Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference Sep 22 2016
Bristol-Myers Opdivo's Regulatory Application Validated in EU Sep 21 2016
Bristol-Myers Capitalizes on Japanese Markets for Its Cardio Drug Sep 21 2016
European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo... Sep 21 2016
How Multiple Research Programs in Lung Cancer Space Are Impacting Bristol-Myers Squibb Sep 20 2016
Multiple Segments of Lung Cancer Create Opportunity for Bristol-Myers Squibb’s Sep 20 2016
European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for... Sep 20 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)